Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment
ConclusionClinicians prescribing ICIs should be aware that SOT recipients are at risk of transplant rejection as a result of T cell activation. Dd-cfDNA is a sensitive biomarker and should be further studied for early detection of transplant rejection. Immunological analysis of the kidney explant showed marked graft infiltration with alloreactive PD-1+ cytotoxic T cells that were saturated with nivolumab.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Bone Graft | Cancer | Cancer & Oncology | Dialysis | Hemodialysis | Immunotherapy | Kidney Transplant | Kidney Transplantation | Melanoma | Nephrectomy | Skin Cancer | Toxicology | Transplant Surgery | Transplants | Urology & Nephrology